LEADER 02329cam a2200505 a 4500001    9972192123506421
005    20231120130024.0
006    m     o  d f
007    cr b||||||||||
008    121023s1979    mdua    ob   f000 0 eng c
027    CAS No. 91-93-0
035    ocn814057448
035    (NjP)7219212-princetondb
035     |z(NjP)Voyager7219212
040    GPO |beng |cGPO |dOCLCO |dOCLCQ |dGPO |dMvI
042    pcc
049    DOCS
074    0507-G-12 (online)
086 0  HE 20.3159/2:128
088    NCI-CG-TR-128
090    Electronic Resource
245 00 Bioassay of 3,3'-dimethoxybenzidine-4,4'-diisocyanate for possible carcinogenicity / |cCarcinogenesis Testing Program, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health.
264  1 Bethesda, Md. : |bU.S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health, |c1979.
300    1 online resource (118 unnumbered pages) : |billustrations.
336    text |btxt |2rdacontent
337    computer |bc |2rdamedia
338    online resource |bcr |2rdacarrier
490 1  Carcinogenesis technical report series ; |vno. 128
490 1  DHEW publication ; |vno. (NIH) 79-1383
500    Title from title screen (viewed on Oct. 23, 2012).
500    "This bioassay of 3,3'-dimethoxybenzidine-4,4'-diisocyanate was conducted by Litton Bionetics, Inc."
504    Includes bibliographical references (pages 56-57).
500    "CAS no. 91-93-0."
500    "NCI-CG-TR-128."
650  0 Carcinogens.
650  0 Polymerization |xToxicology.
710 2  National Cancer Institute (U.S.). |bDivision of Cancer Cause and Prevention.
710 2  Carcinogenesis Testing Program (U.S.)
710 2  National Institutes of Health (U.S.)
710 2  Litton-Bionetics, inc.
776 08  |iPrint version:National Cancer Institute (U.S.). Division of Cancer Cause and Prevention. |tBioassay of 3,3'-dimethoxybenzidine-4,4'-diisocyanate for possible carcinogenicity |w(OCoLC)4510090
830  0 National Cancer Institute carcinogenesis technical report series ; |vno. 128.
830  0 DHEW publication ; |vno. (NIH) 79-1383.
945    DOCS |cHE 20.3159/2:128
956 40  |uhttps://purl.fdlp.gov/GPO/gpo30257